Common use of Reimbursement of Development Costs Clause in Contracts

Reimbursement of Development Costs. The party electing to continue development under the terms of Section 8.5 shall be deemed to be the party who "wishes to develop the Future Blood Screening Assay" described in Section 3.2.1(c) of the Agreement. The provisions of Section 3.2.1(c) and the provisions of Section 3.2.3(b)(i) of the Agreement shall govern the rights and obligations of the parties from and after the effective date of termination under Section 8.2 or the effective date of withdrawal under Section 8.4 of the Ultrio Development Program as a joint development program under this Ultrio Addendum, except Section 3.2.1(b) of the Agreement shall be deleted in its entirety, and replaced with the following.

Reimbursement of Development Costs. The party electing to continue development under the terms of Section 8.5 shall be deemed to be the party who "wishes to develop the Future Blood Screening Assay" described in Section 3.2.1(c) of the Agreement. The provisions of Section 3.2.1(c) and the provisions of Section 3.2.3(b)(i) of the Agreement shall govern the rights and obligations of the parties from and after the effective date of termination under Section 8.2 or the effective date of withdrawal under Section 8.4 of the Ultrio WNV Development Program as a joint development program under this Ultrio West Nile Virus Addendum, except Section 3.2.1(b) of the Agreement shall be deleted in its entirety, and replaced with the following.

Reimbursement of Development Costs. The party electing to continue development under the terms of Section 8.5 shall be deemed to be the party who "“wishes to develop the Future Blood Screening Assay" ” described in Section 3.2.1(c) of the Agreement. The provisions of Section 3.2.1(c) and the provisions of Section 3.2.3(b)(i) of the Agreement shall govern the rights and obligations of the parties from and after the effective date of termination under Section 8.2 or the *** Confidential Treatment Requested 19 effective date of withdrawal under Section 8.4 of the Ultrio 2 Development Program as a joint development program under this Ultrio 2 Addendum, except Section 3.2.1(b) of the Agreement shall be deleted in its entirety, and replaced with the following.

Reimbursement of Development Costs. The party electing to continue development under the terms of Section 8.5 8.4 shall be deemed to be the party who "wishes to develop the Future Blood Screening Assay" described in Section 3.2.1(c) of the Agreement. The provisions of Section 3.2.1(c) and the provisions of Section 3.2.3(b)(i) of the Agreement shall govern the rights and obligations of the parties from and after the effective date of termination under Section 8.2 8.1 or the effective date of withdrawal under Section 8.4 8.3 of the Ultrio WNV Development Program as a joint development program under this Ultrio West Nile Virus Addendum, except Section 3.2.1(b) of the Agreement shall be deleted in its entirety, and replaced with the following.